Bioasis Technologies and testing services provider BioAgilytix will partner on the development and validation of bioanalytical methods to support and advance the xB3 -001 program, Bioasis’ lead candidate to treat HER2+ brain cancer.
Click for full article
Learn how BioAgilytix provides the
See how our PK expertise complements our immunogenicity services by evaluating
Learn why we’re a trusted partner to
What are your specific assay needs? Let’s schedule a conversation to review your
questions and requirements with one of our scientists.
Learn how BioAgilytix provides the
See how our PK expertise complements our immunogenicity services by evaluating
Learn why we’re a trusted partner to
What are your specific assay needs? Let’s schedule a conversation to review your
questions and requirements with one of our scientists.
Services
Platforms